Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

49.70 +0.61 (+1.24%)
Streaming Delayed Price Updated: 10:12 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
2 Surefire Stocks That Could Make You Richer
It won't happen overnight, but with these stocks, a little patience is all you need. 
Via The Motley Fool
(SNY) - Analyzing Sanofi's Short Interest
Via Benzinga
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion. 
Via Investor's Business Daily
Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts
According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX). 
Via Benzinga
What's Going On With Mirati Therapeutics Stock?
Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are trading higher Friday. 
Via Benzinga
Looking Into Sanofi's Recent Short Interest
Via Benzinga
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
Benzinga 
Via Benzinga
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. 
Via Investor's Business Daily
Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and  
Via Benzinga
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c 
Via Benzinga
Why Shares of Kymera Therapeutics Jumped on Tuesday
The company had a big bounce after hitting a 52-week low the day before. 
Via The Motley Fool
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine
Sanofi SA (NASDAQ: SNY) struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize the vaccine candidate for extraintestinal&nb 
Via Benzinga
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
AstraZeneca Plc (NASDAQ: AZN) has  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Read the latest report on NanoViricides here 
Via Benzinga
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
If the biotech does split its stock, it will be a first for the company. 
Via The Motley Fool
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. 
Via Benzinga
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE 
Via Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Read the latest report on NanoViricides here 
Via Benzinga
CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants
Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV 
Via Benzinga
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
Travere Therapeutics Inc (NASDAQ: TVTX) announced 
Via Benzinga
Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis, Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs, Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories
Benzinga 
Via Benzinga
FDA Rejects EpiPen Alternative - ARS Pharmaceuticals' Allergic Reaction Nasal Spray
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type... 
Via Benzinga
Exposures Product Safety
3 Stocks to Buy to Ride Europe’s Coming Market Surge
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.